[go: up one dir, main page]

WO2000065076A3 - Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes - Google Patents

Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes Download PDF

Info

Publication number
WO2000065076A3
WO2000065076A3 PCT/EP2000/003765 EP0003765W WO0065076A3 WO 2000065076 A3 WO2000065076 A3 WO 2000065076A3 EP 0003765 W EP0003765 W EP 0003765W WO 0065076 A3 WO0065076 A3 WO 0065076A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
enzyme
retroviral
gene
integrase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/003765
Other languages
English (en)
Other versions
WO2000065076A2 (fr
Inventor
Zeger Debyser
Clercq Erik De
Peter Cherepanov
Wim Pluymers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Priority to JP2000614410A priority Critical patent/JP2002542791A/ja
Priority to CA002369058A priority patent/CA2369058A1/fr
Priority to IL14609000A priority patent/IL146090A0/xx
Priority to AU45579/00A priority patent/AU778106B2/en
Priority to BR0010077-3A priority patent/BR0010077A/pt
Priority to EP00927069A priority patent/EP1183381A2/fr
Publication of WO2000065076A2 publication Critical patent/WO2000065076A2/fr
Priority to NO20015168A priority patent/NO20015168L/no
Anticipated expiration legal-status Critical
Publication of WO2000065076A3 publication Critical patent/WO2000065076A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un gène synthétique ou une région de gène ayant une utilisation améliorée de codon par rapport au gène de type de sauvage et servant à l'expression de niveau élevé d'une protéine rétrovirale dans des cellules eucariotes, la protéine rétrovirale exprimée possédant une activité enzymatique dans la cellule eucariote. L'invention concerne également un gène synthétique ou une région de gène codant une enzyme rétrovirale ou une partie d'enzyme exprimée normalement dans une cellule mammalienne ou dans une autre cellule eucariote, au moins un codon non préféré dans le gène de type sauvage codant l'enzyme ayant été remplacé par un codon préféré codant le même acide aminé. La protéine rétrovirale peut être une protéase, une transcriptase inverse, une protéine intégrase ou son précurseur gag-pol de polyprotéine. Dans un mode de réalisation la protéine rétrovirale à activité enzymatique est une protéine lentivirale. Dans d'autres modes de réalisation, la protéine à activité enzymatique est une enzyme pol. Dans des modes de réalisation préférés, la protéine à activité enzymatique est une intégrase lentivirale, ou, mieux, une enzyme de VIH; dans d'autres modes de réalisation, la protéine à activité enzymatique est idéalement une intégrase de VIH. L'invention concerne également un procédé de détection de l'intégrase intracellulaire au moyen d'un gène reporter démuni de promoteur.
PCT/EP2000/003765 1999-04-26 2000-04-26 Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes Ceased WO2000065076A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2000614410A JP2002542791A (ja) 1999-04-26 2000-04-26 真核生物中で活性を有するレトロウイルスタンパク質を発現させるための合成遺伝子
CA002369058A CA2369058A1 (fr) 1999-04-26 2000-04-26 Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes
IL14609000A IL146090A0 (en) 1999-04-26 2000-04-26 A synthetic gene for expression of a retroviral protein with wild type activity in eukaryotic cells
AU45579/00A AU778106B2 (en) 1999-04-26 2000-04-26 Synthetic gene for expressing active retroviral protein in eukaryotes
BR0010077-3A BR0010077A (pt) 1999-04-26 2000-04-26 Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas
EP00927069A EP1183381A2 (fr) 1999-04-26 2000-04-26 Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes
NO20015168A NO20015168L (no) 1999-04-26 2001-10-23 Syntetisk gen for ekspresjon av aktivt retroviralt protein i eukaryoter

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99201306 1999-04-26
EP99201306.0 1999-04-26
EP00200171 2000-01-18
EP00200171.7 2000-01-18

Publications (2)

Publication Number Publication Date
WO2000065076A2 WO2000065076A2 (fr) 2000-11-02
WO2000065076A3 true WO2000065076A3 (fr) 2001-12-13

Family

ID=26071747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003765 Ceased WO2000065076A2 (fr) 1999-04-26 2000-04-26 Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes

Country Status (11)

Country Link
EP (1) EP1183381A2 (fr)
JP (1) JP2002542791A (fr)
AU (1) AU778106B2 (fr)
BR (1) BR0010077A (fr)
CA (1) CA2369058A1 (fr)
HU (1) HUP0201019A2 (fr)
IL (1) IL146090A0 (fr)
NO (1) NO20015168L (fr)
PL (1) PL351988A1 (fr)
RU (1) RU2001131728A (fr)
WO (1) WO2000065076A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
CA2358385C (fr) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
JP4627950B2 (ja) * 1999-12-23 2011-02-09 アメリカ合衆国 変異ＨＩＶｇａｇ／ｐｏｌ、ＳＩＶｇａｇおよびＳＩＶｅｎｖ遺伝子を持つ分子クローン
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
AUPQ580300A0 (en) * 2000-02-23 2000-03-16 National Cancer Centre Of Singapore Pte Ltd Genetic analysis
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
JP4385135B2 (ja) * 2003-05-06 2009-12-16 独立行政法人産業技術総合研究所 マルチ遺伝子転写活性測定システム
US8106176B2 (en) 2005-10-07 2012-01-31 Instituto di Richerche di Biologia Molecolare P. Angeletti SpA Matrix metalloproteinase 11 vaccine
JP6824594B2 (ja) 2014-09-11 2021-02-03 Jnc株式会社 合成遺伝子の設計方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
US5468629A (en) * 1993-04-13 1995-11-21 Calhoun; Cornelia Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein
WO1997036481A1 (fr) * 1996-04-02 1997-10-09 The Regents Of The University Of California Conception de nouveaux systemes d'encapsulation de type vih d'une grande efficacite en vue d'une therapie genique
WO1998012207A1 (fr) * 1996-09-20 1998-03-26 The General Hospital Corporation Expression puissante de proteines
WO1998034640A2 (fr) * 1997-02-07 1998-08-13 Merck & Co., Inc. Genes synthetiques du gag hiv
US5811270A (en) * 1994-05-20 1998-09-22 Grandgenett; Duane P. In vitro method for concerted integration of donor DNA molecules using retroviral integrase proteins
WO2000039302A2 (fr) * 1998-12-31 2000-07-06 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358385C (fr) * 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468629A (en) * 1993-04-13 1995-11-21 Calhoun; Cornelia Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
US5811270A (en) * 1994-05-20 1998-09-22 Grandgenett; Duane P. In vitro method for concerted integration of donor DNA molecules using retroviral integrase proteins
WO1997036481A1 (fr) * 1996-04-02 1997-10-09 The Regents Of The University Of California Conception de nouveaux systemes d'encapsulation de type vih d'une grande efficacite en vue d'une therapie genique
WO1998012207A1 (fr) * 1996-09-20 1998-03-26 The General Hospital Corporation Expression puissante de proteines
WO1998034640A2 (fr) * 1997-02-07 1998-08-13 Merck & Co., Inc. Genes synthetiques du gag hiv
WO2000039302A2 (fr) * 1998-12-31 2000-07-06 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BUSHMAN, F. D. ET AL.: "Retroviral DNA integration directed by HIV integration protein in vitro", SCIENCE, vol. 249, 28 September 1990 (1990-09-28), LANCASTER, PA US, pages 1555 - 1558, XP000953086 *
CHEREPANOV P, SURRATT D, TOELEN J, PLUYMERS W, GRIFFITH J, DE CLERCQ E, DEBYSER Z.: "Activity of recombinant HIV-1 integrase on mini-HIV DNA.", NUCLEIC ACIDS RES. 1999 MAY 15;27(10):2202-10., 15 May 1999 (1999-05-15), XP000877353 *
HAAS J ET AL: "CODON USAGE LIMITATION IN THE EXPRESSION OF HIV-1 ENVELOPE GLYCOPROTEIN", CURRENT BIOLOGY,GB,CURRENT SCIENCE,, vol. 6, no. 3, 1 March 1996 (1996-03-01), pages 315 - 324, XP000619599, ISSN: 0960-9822 *
HOLLER T P ET AL: "HIV1 INTEGRASE EXPRESSED IN ESCHERICHIA COLI FROM A SYNTHETIC GENE", GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 136, 22 December 1993 (1993-12-22), pages 323 - 328, XP000199775, ISSN: 0378-1119 *
KATZ, R.A. ET AL.: "The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro", CELL, vol. 63, 5 October 1990 (1990-10-05), CELL PRESS, CAMBRIDGE, NA., US, pages 87 - 95, XP000953087, ISSN: 0092-8674 *
KOTSOPOULOU E. ET AL.: "A REV-INDEPENDENT HUMAN IMMUNODEFICINCY VIRUS TYPE 1 (HIV-1)-BASED VECTOR THAT EXPLOITS A CODON OPTIMIZED HIV-1 GAG-POL GENE", JOURNAL OF VIROLOGY., vol. 74, no. 10, May 2000 (2000-05-01), ICAN SOCIETY FOR MICROBIOLOGY US, pages 4839 - 4852, XP002152133 *
SCHNEIDER R ET AL: "Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows rev-independent expression of gag and gag/protease and particle formation", JOURNAL OF VIROLOGY,THE AMERICAN SOCIETY FOR MICROBIOLOGY,US, vol. 71, no. 7, July 1997 (1997-07-01), pages 4892 - 4903, XP002137891, ISSN: 0022-538X *
ZUR MEGEDE J, CHEN MC, DOE B, SCHAEFER M, GREER CE, SELBY M, OTTEN GR, BARNETT SW: "Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.", J VIROL 2000 MAR;74(6):2628-35, XP002157414 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
IL146090A0 (en) 2002-07-25
WO2000065076A2 (fr) 2000-11-02
CA2369058A1 (fr) 2000-11-02
AU4557900A (en) 2000-11-10
AU778106B2 (en) 2004-11-18
NO20015168L (no) 2001-12-14
PL351988A1 (en) 2003-07-14
NO20015168D0 (no) 2001-10-23
EP1183381A2 (fr) 2002-03-06
JP2002542791A (ja) 2002-12-17
RU2001131728A (ru) 2004-02-20
BR0010077A (pt) 2002-01-15
HUP0201019A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
WO2000065076A3 (fr) Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes
Stark et al. Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: implications for priming of HIV-1 reverse transcription
Fusek et al. Enzymic properties of thermopsin.
Tanchou et al. Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication
Harari et al. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H
Bulter et al. Functional expression of a fungal laccase in Saccharomyces cerevisiae by directed evolution
Lu et al. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase
Coleman et al. Sensitive, coupled assay for plasminogen activator using a thiol ester substrate for plasmin
EP0142690A3 (fr) Senseur enzymatique pour gaz toxique
ATE450635T1 (de) Elektrochemische herstellung von peroxo- dischwefelsäure unter einsatz von diamantbeschichteten elektroden
IL128564A0 (en) Lentiviral vectors
ES2150188T3 (es) Procedimiento para la preparacion de una proteina mediante un hongo transformado por integracion multicopia de un vector de expresion.
WO2001044286A3 (fr) Proteine a cinq helices
WO2001049247A3 (fr) Utilisation d'analogues de nicotinamide adenine dinucleotide (nad) et analogues de nicotinamide adenine dinucleotide phosphate (nadp) pour la mesure des activites enzymatiques, de metabolites et de substrats
JP2008161178A5 (fr)
Kovačević et al. Influence of methionine residue position on oxidative stability of glucose oxidase from Aspergillus niger
AU2001244074A1 (en) Enzymatic-electrochemical measuring device
Takase Effect of mutation of an amino acid residue near the catalytic site on the activity of Bacillus stearothermophilusα‐amylase
Menéndez-Arias Studies on the Effects of Truncating α-Helix E ‘of p66 Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Template− Primer Binding and Fidelity of DNA Synthesis
WO2004029196A3 (fr) Methodes permettant de determiner l'effet d'un agent sur des cellules diploides et/ou sur le processus d'expression de polypeptides exprimes par cet agent
WO1998053104A3 (fr) Detection de sous-types retroviraux basee sur des sequences specifiques d'une enveloppe
Buchberger Control of ubiquitin conjugation by cdc48 and its cofactors
WO1999037758A3 (fr) Expression de peptides sensibles a la proteolyse
DK1305406T3 (da) Modulering af gamma-sekretaseaktivitet
Herrera‐Camacho et al. Aminopeptidase yscCo‐II: a new cobalt‐dependent aminopeptidase from yeast—purification and biochemical characterization

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2369058

Country of ref document: CA

Ref document number: 2000 614410

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000927069

Country of ref document: EP

Ref document number: 45579/00

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000927069

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10019359

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000927069

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 45579/00

Country of ref document: AU